GLORIA-AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III-India and Switzerland)

Trial Profile

GLORIA-AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III-India and Switzerland)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Dabigatran etexilate (Primary)
  • Indications Atrial fibrillation; Stroke
  • Focus Therapeutic Use
  • Acronyms GLORIA-AF
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 04 Dec 2016 The results were presented at the American Society of Hematology (ASH) Annual Meeting, as reported by Boehringer Ingelheim media release.
    • 04 Dec 2016 Results published in the Boehringer Ingelheim Media Release
    • 30 Aug 2016 Results from this trial presented at the ESC Congress 2016, as reported by Boehringer Ingelheim media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top